Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), Gran Via 199, L'Hospitalet del Llobregat 08908, Spain.
Breast Cancer Res. 2011 Apr 5;13(2):R40. doi: 10.1186/bcr2862.
Proteins encoded by Fanconi anemia (FA) and/or breast cancer (BrCa) susceptibility genes cooperate in a common DNA damage repair signaling pathway. To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens.
Protein physical interactions were screened using the yeast two-hybrid system. Co-affinity purifications and endogenous co-immunoprecipitation assays were performed to corroborate interactions. Biochemical and functional assays in human, mouse and Caenorhabditis elegans models were carried out to characterize pathway components. Thirteen FANCD2-monoubiquitinylation-positive FA cell lines excluded for genetic defects in the downstream pathway components and 300 familial BrCa patients negative for BRCA1/2 mutations were analyzed for genetic mutations. Common genetic variants were genotyped in 9,573 BRCA1/2 mutation carriers for associations with BrCa risk.
A previously identified co-purifying protein with PALB2 was identified, MRG15 (MORF4L1 gene). Results in human, mouse and C. elegans models delineate molecular and functional relationships with BRCA2, PALB2, RAD51 and RPA1 that suggest a role for MRG15 in the repair of DNA double-strand breaks. Mrg15-deficient murine embryonic fibroblasts showed moderate sensitivity to γ-irradiation relative to controls and reduced formation of Rad51 nuclear foci. Examination of mutants of MRG15 and BRCA2 C. elegans orthologs revealed phenocopy by accumulation of RPA-1 (human RPA1) nuclear foci and aberrant chromosomal compactions in meiotic cells. However, no alterations or mutations were identified for MRG15/MORF4L1 in unclassified FA patients and BrCa familial cases. Finally, no significant associations between common MORF4L1 variants and BrCa risk for BRCA1 or BRCA2 mutation carriers were identified: rs7164529, Ptrend = 0.45 and 0.05, P2df = 0.51 and 0.14, respectively; and rs10519219, Ptrend = 0.92 and 0.72, P2df = 0.76 and 0.07, respectively.
While the present study expands on the role of MRG15 in the control of genomic stability, weak associations cannot be ruled out for potential low-penetrance variants at MORF4L1 and BrCa risk among BRCA2 mutation carriers.
范可尼贫血(FA)和/或乳腺癌(BrCa)易感性基因编码的蛋白质在共同的 DNA 损伤修复信号通路中相互协作。为了更深入地了解该通路及其对癌症风险的影响,我们通过蛋白质物理相互作用筛选寻找新的成分。
使用酵母双杂交系统筛选蛋白质物理相互作用。进行共亲和纯化和内源性共免疫沉淀测定以证实相互作用。在人、鼠和秀丽隐杆线虫模型中进行生化和功能测定,以鉴定通路成分。对排除下游通路成分遗传缺陷的十三株 FANCD2 单泛素化阳性 FA 细胞系和 300 例 BRCA1/2 突变阴性的家族性 BrCa 患者进行遗传突变分析。对 9573 名 BRCA1/2 突变携带者的常见遗传变异进行基因分型,以研究其与 BrCa 风险的关联。
鉴定到先前与 PALB2 共纯化的蛋白,MRG15(MORF4L1 基因)。在人、鼠和 C. elegans 模型中的结果描绘了与 BRCA2、PALB2、RAD51 和 RPA1 的分子和功能关系,提示 MRG15 在 DNA 双链断裂修复中起作用。与对照相比,Mrg15 缺陷型鼠胚胎成纤维细胞对 γ 辐射的敏感性中度增加,且 Rad51 核焦点形成减少。对 MRG15 和 BRCA2 秀丽隐杆线虫同源物的突变体进行检查,发现 RPA-1(人 RPA1)核焦点和减数分裂细胞中异常染色体浓缩的积累可导致表型复制。然而,在未分类的 FA 患者和家族性 BrCa 病例中未发现 MRG15/MORF4L1 的改变或突变。最后,未发现常见的 MORF4L1 变异与 BRCA1 或 BRCA2 突变携带者的 BrCa 风险之间存在显著关联:rs7164529,Ptrend = 0.45 和 0.05,P2df = 0.51 和 0.14,分别;和 rs10519219,Ptrend = 0.92 和 0.72,P2df = 0.76 和 0.07,分别。
虽然本研究扩展了 MRG15 在控制基因组稳定性中的作用,但对于 BRCA2 突变携带者中潜在的低外显率变体与 MORF4L1 和 BrCa 风险之间的弱关联,仍不能排除。